Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive OfficerAccesswire • 05/30/23
Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side EffectsAccesswire • 05/15/23
Biofrontera Inc. (BFRI) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/12/23
Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business UpdateAccesswire • 05/12/23
Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer PreventionAccesswire • 05/09/23
Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)Accesswire • 04/26/23
CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial ResultsAccesswire • 03/09/23
Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial ResultsAccesswire • 03/08/23
Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023Accesswire • 03/02/23
Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023Accesswire • 02/22/23
Biofrontera, Inc. to Present at Third Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 21st – 24th, 2023Accesswire • 02/15/23
Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and TrunkAccesswire • 01/09/23
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022Accesswire • 01/09/23
Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of StockholdersGlobeNewsWire • 12/16/22
Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investor ConferenceGlobeNewsWire • 11/30/22
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022GlobeNewsWire • 11/28/22
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and TrunkGlobeNewsWire • 11/21/22